Patient Selection for Immunomodulation

Uses

Benefits

Comparisons

Evidence quality

Highlighted claims

• A biomarker substudy of pre-randomisation MATIS samples is underway to assess whether immune phenotypes can guide immunomodulator choice. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
• The key lesson from MATIS and parallel trials is that patient selection for immunomodulation requires greater precision than a single CRP threshold. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
• The CRP-only entry criterion of ≥30 mg/L used in MATIS may have been insufficiently specific to identify hyperinflammatory phenotypes most likely to benefit from immunomodulation. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
• MATIS results are expected to inform management of other virally induced multisystemic hyperinflammatory disorders beyond COVID-19. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
• Emerging evidence on host genetic factors predisposing to exaggerated hyperinflammatory responses may allow individualised therapy selection. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic